Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.87
-1.09 (-3.21%)
At close: Mar 17, 2026, 4:00 PM EDT
32.87
0.00 (0.00%)
After-hours: Mar 17, 2026, 4:54 PM EDT

Stoke Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
184.4236.568.7812.41-
Revenue Growth (YoY)
404.50%316.34%-29.22%--
Gross Profit
184.4236.568.7812.41-
Selling, General & Admin
67.0948.7941.3238.9231.9
Research & Development
137.9289.1382.2377.8454.17
Total Operating Expenses
205.01137.93123.55116.7686.07
Operating Income
-20.59-101.37-114.77-104.36-86.07
Interest Income
13.7612.649.913.120.12
Other Non-Operating Income (Expense)
-0.05-0.250.170.170.14
Total Non-Operating Income (Expense)
13.7112.3910.073.290.26
Pretax Income
-6.89-88.98-104.7-101.07-85.81
Net Income
-6.89-88.98-104.7-101.07-85.81
Net Income to Common
-6.89-88.98-104.7-101.07-85.81
Shares Outstanding (Basic)
5954443937
Shares Outstanding (Diluted)
5954443937
Shares Change (YoY)
9.65%22.76%13.11%5.87%9.71%
EPS (Basic)
-0.12-1.65-2.38-2.60-2.34
EPS (Diluted)
-0.12-1.65-2.38-2.60-2.34
Free Cash Flow
44.92-87.05-82.68-35.83-68.11
Free Cash Flow Per Share
0.76-1.61-1.88-0.92-1.85
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-11.16%-277.31%-1307.21%-841.24%-
Profit Margin
-3.73%-243.42%-1192.47%-814.73%-
FCF Margin
24.35%-238.15%-941.72%-288.82%-
EBITDA
-18.82-99.2-112.3-102.81-85.09
EBITDA Margin
-10.20%-271.36%-1279.09%-828.78%-
EBIT
-20.59-101.37-114.77-104.36-86.07
EBIT Margin
-11.16%-277.31%-1307.21%-841.24%-
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q